Immunocore Limited is recalling the batches listed below as a precautionary measure. The recall is due to a decrease in potency identified during stability testing. All other stability test results remain within specification.
These reports outline the MHRA’s Corporate and Business Plans, detailing the agency’s strategic direction over the next three years.
The new Business Plan sets out priorities for 2025–26: Protecting public safety and maintaining public trust; delivering efficient, predictable services through regulatory excellence; being an agile organisation that drives innovation; being a great place to work and providing excellent customer service.
How to apply for a clinical trial from 28 April 2026, including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Clinical trial applications that need expert advice from a specialist group or committee.
Guidance on labelling for medicinal products used in clinical trials.
Guidance on categorising certain clinical trials as ‘notifiable’.
Guidance on the process for ending a clinical trial.
Guidance on the various types of modifications that can be made to a clinical trial approval.
Guidance on transitional arrangements for applying for clinical trial approval.
Guidance on using non-investigational medicinal products in a clinical trial.
Guidance on the collection, verification, and reporting of safety events in clinical trials of an investigational medicinal product.
